Clinical effectiveness of ezetimibe for a non-obese patient with nonalcoholic fatty liver disease

Munechika Enjoji, Masatake Tanaka, Masayuki Miyazaki, Nobito Higuchi, Masaki Kato, Kazuhiro Kotoh, Kazuhisa Matsunaga, Takuya Nishinakagawa, Kazuyuki Machida, Manabu Nakashima, Makoto Nakamuta

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and compared these factors between nonobese and obese individuals. We found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, the dietary cholesterol intake was superabundant and the dietary intake of polyunsaturated fatty acids was significantly lower in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, surplus cholesterol intake appears to be a factor associated with NAFLD development and liver injury. Case Report: In a non-obese 48-year-old male patient with NAFLD, in whom ursodeoxycholic acid and tocopherol acetate treatments were not effective, we tested a novel approach using the cholesterol absorption inhibitor ezetimibe. Without any dietary or exercise modification, 10 mg/day of ezetimibe was started instead of tocopherol acetate. Although body weight and body mass index remained nearly constant, the serum levels of transaminases promptly decreased into the normal range, which was accompanied by a decrease in serum total cholesterol and LDL-cholesterol exceeding 10%. Conclusions: Ezetimibe may offer a novel treatment for NAFLD, particularly in non-obese patients.

Original languageEnglish
Pages (from-to)145-148
Number of pages4
JournalAmerican Journal of Case Reports
Volume10
Publication statusPublished - Dec 1 2009

Fingerprint

alpha-Tocopherol
Cholesterol
Anticholesteremic Agents
Dietary Cholesterol
Ursodeoxycholic Acid
Abdominal Fat
Adipokines
Transaminases
Energy Intake
Serum
Unsaturated Fatty Acids
LDL Cholesterol
Insulin Resistance
Non-alcoholic Fatty Liver Disease
Ezetimibe
Reference Values
Body Mass Index
Body Weight
Carbohydrates
Exercise

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Clinical effectiveness of ezetimibe for a non-obese patient with nonalcoholic fatty liver disease. / Enjoji, Munechika; Tanaka, Masatake; Miyazaki, Masayuki; Higuchi, Nobito; Kato, Masaki; Kotoh, Kazuhiro; Matsunaga, Kazuhisa; Nishinakagawa, Takuya; Machida, Kazuyuki; Nakashima, Manabu; Nakamuta, Makoto.

In: American Journal of Case Reports, Vol. 10, 01.12.2009, p. 145-148.

Research output: Contribution to journalArticle

Enjoji, M, Tanaka, M, Miyazaki, M, Higuchi, N, Kato, M, Kotoh, K, Matsunaga, K, Nishinakagawa, T, Machida, K, Nakashima, M & Nakamuta, M 2009, 'Clinical effectiveness of ezetimibe for a non-obese patient with nonalcoholic fatty liver disease', American Journal of Case Reports, vol. 10, pp. 145-148.
Enjoji, Munechika ; Tanaka, Masatake ; Miyazaki, Masayuki ; Higuchi, Nobito ; Kato, Masaki ; Kotoh, Kazuhiro ; Matsunaga, Kazuhisa ; Nishinakagawa, Takuya ; Machida, Kazuyuki ; Nakashima, Manabu ; Nakamuta, Makoto. / Clinical effectiveness of ezetimibe for a non-obese patient with nonalcoholic fatty liver disease. In: American Journal of Case Reports. 2009 ; Vol. 10. pp. 145-148.
@article{ea15c8d0d9d642dfaa7fe95ebf355e6c,
title = "Clinical effectiveness of ezetimibe for a non-obese patient with nonalcoholic fatty liver disease",
abstract = "Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and compared these factors between nonobese and obese individuals. We found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, the dietary cholesterol intake was superabundant and the dietary intake of polyunsaturated fatty acids was significantly lower in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, surplus cholesterol intake appears to be a factor associated with NAFLD development and liver injury. Case Report: In a non-obese 48-year-old male patient with NAFLD, in whom ursodeoxycholic acid and tocopherol acetate treatments were not effective, we tested a novel approach using the cholesterol absorption inhibitor ezetimibe. Without any dietary or exercise modification, 10 mg/day of ezetimibe was started instead of tocopherol acetate. Although body weight and body mass index remained nearly constant, the serum levels of transaminases promptly decreased into the normal range, which was accompanied by a decrease in serum total cholesterol and LDL-cholesterol exceeding 10{\%}. Conclusions: Ezetimibe may offer a novel treatment for NAFLD, particularly in non-obese patients.",
author = "Munechika Enjoji and Masatake Tanaka and Masayuki Miyazaki and Nobito Higuchi and Masaki Kato and Kazuhiro Kotoh and Kazuhisa Matsunaga and Takuya Nishinakagawa and Kazuyuki Machida and Manabu Nakashima and Makoto Nakamuta",
year = "2009",
month = "12",
day = "1",
language = "English",
volume = "10",
pages = "145--148",
journal = "American Journal of Case Reports",
issn = "1941-5923",
publisher = "International Scientific Literature, Inc",

}

TY - JOUR

T1 - Clinical effectiveness of ezetimibe for a non-obese patient with nonalcoholic fatty liver disease

AU - Enjoji, Munechika

AU - Tanaka, Masatake

AU - Miyazaki, Masayuki

AU - Higuchi, Nobito

AU - Kato, Masaki

AU - Kotoh, Kazuhiro

AU - Matsunaga, Kazuhisa

AU - Nishinakagawa, Takuya

AU - Machida, Kazuyuki

AU - Nakashima, Manabu

AU - Nakamuta, Makoto

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and compared these factors between nonobese and obese individuals. We found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, the dietary cholesterol intake was superabundant and the dietary intake of polyunsaturated fatty acids was significantly lower in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, surplus cholesterol intake appears to be a factor associated with NAFLD development and liver injury. Case Report: In a non-obese 48-year-old male patient with NAFLD, in whom ursodeoxycholic acid and tocopherol acetate treatments were not effective, we tested a novel approach using the cholesterol absorption inhibitor ezetimibe. Without any dietary or exercise modification, 10 mg/day of ezetimibe was started instead of tocopherol acetate. Although body weight and body mass index remained nearly constant, the serum levels of transaminases promptly decreased into the normal range, which was accompanied by a decrease in serum total cholesterol and LDL-cholesterol exceeding 10%. Conclusions: Ezetimibe may offer a novel treatment for NAFLD, particularly in non-obese patients.

AB - Background: We recently examined the distribution of abdominal fat, dietary intake and biochemical data in patients with nonalcoholic fatty liver disease (NAFLD) and compared these factors between nonobese and obese individuals. We found that non-obese NAFLD patients did not necessarily exhibit insulin resistance and/or dysregulated secretion of adipocytokines. However, the dietary cholesterol intake was superabundant and the dietary intake of polyunsaturated fatty acids was significantly lower in non-obese patients compared with obese patients, although total energy and carbohydrate intake was not excessive. Therefore, surplus cholesterol intake appears to be a factor associated with NAFLD development and liver injury. Case Report: In a non-obese 48-year-old male patient with NAFLD, in whom ursodeoxycholic acid and tocopherol acetate treatments were not effective, we tested a novel approach using the cholesterol absorption inhibitor ezetimibe. Without any dietary or exercise modification, 10 mg/day of ezetimibe was started instead of tocopherol acetate. Although body weight and body mass index remained nearly constant, the serum levels of transaminases promptly decreased into the normal range, which was accompanied by a decrease in serum total cholesterol and LDL-cholesterol exceeding 10%. Conclusions: Ezetimibe may offer a novel treatment for NAFLD, particularly in non-obese patients.

UR - http://www.scopus.com/inward/record.url?scp=77449111031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449111031&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 145

EP - 148

JO - American Journal of Case Reports

JF - American Journal of Case Reports

SN - 1941-5923

ER -